Direct answer: Novo Nordisk makes both Ozempic and Wegovy. Both are FDA-approved prescription products containing semaglutide, but they have separate labels, presentations, and approved uses. Compounded semaglutide is not manufactured by Novo Nordisk and is not an FDA-approved version of either brand.
Editorial note: FormBlends reviewed this page on August 11, 2026 against current FDA labeling, FDA supply notices, and Novo Nordisk corporate filings. It was prepared by the FormBlends Editorial Team; no clinician review is claimed.
Manufacturer facts at a glance
| Question | Verified answer | Primary evidence |
|---|---|---|
| Who makes Ozempic? | Novo Nordisk | Current Ozempic label on DailyMed |
| Who makes Wegovy? | Novo Nordisk | Current Wegovy label on DailyMed |
| What active ingredient do they share? | Semaglutide | The active ingredient is identified in both FDA-approved labels. |
| Who makes compounded semaglutide? | A compounding pharmacy or outsourcing facility, not Novo Nordisk | FDA information on unapproved GLP-1 drugs |
Are Ozempic and Wegovy made by the same company?
Yes. The current U.S. prescribing information for both products identifies Novo Nordisk. Novo Nordisk also lists Ozempic and Wegovy in its product portfolio and financial reporting.
That shared manufacturer does not make the brand names interchangeable. Ozempic and Wegovy are separately labeled prescription products. Their approved uses, dosage forms, strengths, and instructions can change as FDA approves labeling updates, so the current prescribing information, not an undated summary, should be the source of truth.
How Ozempic and Wegovy differ
Both products contain semaglutide, a GLP-1 receptor agonist. The practical distinction is the FDA-approved product label:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- Ozempic is an injectable semaglutide product with its own FDA-approved indications and prescribing instructions.
- Wegovy has separate FDA-approved labeling and is available in presentations described in the current Wegovy label.
- A treatment change is a clinical decision. Sharing an active ingredient does not mean a patient should substitute one product for another without guidance from a licensed prescriber.
Because labels can be revised, this page intentionally does not reproduce a complete dosing schedule. Use the linked prescribing information and your clinician's instructions for current product-specific guidance.
Where are Ozempic and Wegovy manufactured?
Novo Nordisk operates a global manufacturing network and has publicly described capacity investments for active pharmaceutical ingredient production, fill-finish operations, and packaging. Its reporting discusses expansions in Denmark, France, the United States, and other markets.
Important limitation: the public product labels and corporate reports do not provide a stable, product-by-product percentage showing exactly how much Ozempic or Wegovy comes from each facility. For that reason, FormBlends does not assign unsupported production percentages to individual plants.
Primary company disclosures include Novo Nordisk's 2025 annual report, its Chartres capacity announcement, and its Clayton capacity announcement.
What is the current U.S. supply status?
FDA announced on February 21, 2025 that the national shortage of semaglutide injection products was resolved. FDA said the manufacturer's availability and capacity could meet present and projected national demand, while warning that intermittent, localized supply disruptions could still occur as products move through the supply chain.
For the latest status, use the FDA semaglutide supply notice and the FDA Drug Shortages Database. A pharmacy-level stock problem does not necessarily mean FDA has declared a national shortage.
Does Novo Nordisk make compounded semaglutide?
No. A compounded semaglutide drug is prepared by a compounding pharmacy or outsourcing facility. It is not manufactured by Novo Nordisk, and it is not an FDA-approved generic version of Ozempic or Wegovy.
FDA says compounded drugs may be appropriate when a patient's medical need cannot be met by an FDA-approved drug, but compounded drugs do not undergo FDA premarket review for safety, effectiveness, or quality. FDA has also warned about dosing errors, adverse-event reports, and semaglutide salt forms in unapproved products. See FDA's current safety information.
How FormBlends verified the answer
- Checked the current Ozempic and Wegovy labeling in the National Library of Medicine's DailyMed database.
- Confirmed the manufacturer and product portfolio in Novo Nordisk's current corporate reporting.
- Checked FDA's national shortage determination and current compounding guidance.
- Removed production-share estimates, patent forecasts, revenue conversions, and clinical switching instructions that could not be supported by the cited primary documents.
Last evidence review: September 4, 2026 (company facts and pricing news added; manufacturer verification unchanged from August 11, 2026). Product labels and regulatory policies can change; the linked primary documents take precedence over this summary.
Novo Nordisk at a glance (September 2026)
People searching for the maker of Ozempic usually want a few company facts next. These are taken from Novo Nordisk's own pages on September 4, 2026.
| Question | Answer | Where it comes from |
|---|---|---|
| Headquarters | Novo Nordisk A/S, Novo Alle 1, 2880 Bagsvaerd, Denmark | novonordisk.com, Who we are |
| Founded | 1923, in Denmark | novonordisk.com, Who we are |
| Employees | More than 69,000 people in 80 offices; 69,505 worldwide at the end of 2025 | Who we are; Annual Report 2025 |
| Chief executive | Maziar Mike Doustdar, President and CEO; Lars Rebien Soerensen chairs the board | Annual Report 2025 |
| Publicly traded? | Yes. Share and listing details are on the company's investor pages | novonordisk.com/investors |
| Products that share semaglutide | Ozempic, Wegovy (pen, HD pen and pill), Rybelsus | FDA labeling; NovoCare |
We have not listed an ownership percentage or a ticker symbol because we could not confirm them on a Novo Nordisk page during this review; the investor pages linked above are the place to check.
Where Ozempic and Wegovy are made in the United States, and who makes the pills
Novo Nordisk's largest disclosed U.S. expansion is in Clayton, North Carolina. On June 24, 2024 the company announced a 4.1 billion dollar investment to build a second fill-and-finish facility there, adding 1.4 million square feet of aseptic manufacturing and finished-production space, doubling the combined footprint of its three existing North Carolina facilities, and adding about 1,000 jobs to the nearly 2,500 Novo Nordisk employees already in the region. The announcement describes the site as capacity for current and future injectable treatments for obesity and other chronic diseases, which is the category Ozempic and Wegovy belong to. As the section above notes, Novo does not publish a product-by-product share for any plant, so we do not assign one.
The oral products have the same manufacturer. Novo Nordisk makes Rybelsus (oral semaglutide for type 2 diabetes) and the Wegovy pill (oral semaglutide for weight management); NovoCare lists the Wegovy pill at the same $1,349.02 per-package list price as the pen. For current pill and pen self-pay prices, see our Wegovy cost guide.
Recent company news that affects patients (2025 to 2026)
- September 10, 2025: Novo Nordisk announced it would cut about 9,000 jobs, per BBC News.
- February 24, 2026: Novo Nordisk said Wegovy (injection and pill), Ozempic and Rybelsus will move to a $675 monthly U.S. list price on January 1, 2027, per CNBC; the Wegovy products currently list at about $1,350 and the diabetes products at about $1,027. The change targets insured patients paying coinsurance or deductibles; self-pay prices are already lower.
- Leadership: Novo's Annual Report 2025 is signed by President and CEO Maziar Mike Doustdar and board chair Lars Rebien Soerensen.
None of these items changes the answer to the question in the title. Novo Nordisk makes Ozempic and Wegovy; compounded semaglutide is made by pharmacies, not by Novo Nordisk.
FAQ
Who manufactures Ozempic and Wegovy?
Novo Nordisk manufactures both Ozempic and Wegovy. The current U.S. prescribing information for each product identifies Novo Nordisk as the company responsible for the product.
Are Ozempic and Wegovy made by the same company?
Yes. Novo Nordisk makes both products. Both contain semaglutide, but they are separately approved products with different FDA labeling, presentations, and uses.
Does Novo Nordisk make compounded semaglutide?
No. Compounded semaglutide is prepared by a compounding pharmacy or outsourcing facility, not by Novo Nordisk, and compounded drugs are not FDA-approved versions of Ozempic or Wegovy.
Are Ozempic and Wegovy the same medication?
They contain the same active ingredient, semaglutide, but they are not interchangeable product names. Their FDA-approved labeling, dosage forms, strengths, and uses differ. A licensed clinician should guide any treatment change.
Are Ozempic and Wegovy still in shortage?
FDA announced on February 21, 2025 that the national shortage of semaglutide injection products was resolved. FDA also noted that intermittent, localized supply disruptions could still occur.
Who makes Ozempic and Mounjaro?
Different companies. Novo Nordisk makes Ozempic (semaglutide). Eli Lilly and Company makes Mounjaro and Zepbound (tirzepatide); Lilly publishes Mounjaro's savings terms at mounjaro.lilly.com. The two molecules are not interchangeable, and a switch between them is a clinical decision for a licensed prescriber.
Is the company that makes Ozempic publicly traded?
Yes. Novo Nordisk A/S is a publicly traded Danish company headquartered in Bagsvaerd, Denmark, founded in 1923, with 69,505 employees worldwide at the end of 2025 according to its Annual Report 2025. Its investor pages at novonordisk.com carry share and listing details; FormBlends does not give investment advice.
Related guides
Primary sources
- DailyMed: current Ozempic prescribing information
- DailyMed: current Wegovy prescribing information
- FDA: semaglutide shortage resolution and compounding transition policy
- FDA: concerns with unapproved GLP-1 drugs used for weight loss
- Novo Nordisk Annual Report 2025
- Novo Nordisk: Who we are (headquarters, founding year, employees), read September 4, 2026
- Novo Nordisk: 4.1 billion USD investment to expand US manufacturing capacity in Clayton, North Carolina, June 24, 2024
- Novo Nordisk: Investors
- NovoCare: Wegovy pen and Wegovy pill list price per package, read September 4, 2026
- CNBC: Novo Nordisk to slash Wegovy, Ozempic U.S. list prices by up to 50 percent, February 24, 2026
- BBC News: Ozempic-maker Novo Nordisk to cut 9,000 jobs, September 10, 2025
Medical and affiliation notices
This article is for general information and does not provide medical advice. Do not start, stop, switch, or change the dose of a prescription medication without guidance from a licensed clinician.
FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →